↓ Skip to main content

Dove Medical Press

Article Metrics

Clinicopathological significance and potential drug target of RUNX3 in non-small cell lung cancer: a meta-analysis

Overview of attention for article published in Drug Design, Development and Therapy, June 2015
Altmetric Badge

Mentioned by

reddit
1 Redditor

Citations

dimensions_citation
13 Dimensions

Readers on

mendeley
20 Mendeley
Title
Clinicopathological significance and potential drug target of RUNX3 in non-small cell lung cancer: a meta-analysis
Published in
Drug Design, Development and Therapy, June 2015
DOI 10.2147/dddt.s76358
Pubmed ID
Authors

Lijun Xu, Jingwen Wan, Jun Li, Yushu Su, Lan Hongwen

Abstract

Emerging evidence indicates that RUNX3 is a candidate tumor suppressor in several types of human tumors, including non-small cell lung cancer (NSCLC). However, the correlation between RUNX3 hypermethylation and clinicopathological characteristics of NSCLC remains unclear. Here, we conducted a systematic review and meta-analysis to quantitatively evaluate the effects of RUNX3 hypermethylation on the incidence of NSCLC and clinicopathological characteristics. A detailed literature search was made using Medline, Embase and Web of Science for related research publications written in English. The methodological quality of the studies was evaluated. The data were extracted and assessed independently by two reviewers. Analysis of pooled data was performed. The odds ratio (OR) and hazard ratio were calculated and summarized. Final analysis of 911 NSCLC patients from 13 eligible studies was performed. We observed that RUNX3 hypermethylation was significantly higher in NSCLC than in normal lung tissue; the pooled OR from seven studies including 361 NSCLC and 345 normal lung tissue (OR 7.08, confidence interval 4.12-12.17, P<0.00001). RUNX3 hypermethylation may also be associated with pathological types. The pooled OR was obtained from eleven studies including 271 squamous cell carcinoma and 389 adenocarcinoma (OR 0.41, confidence interval 0.19-0.89, P=0.02), which indicated that RUNX3 hypermethylation is significantly higher in adenocarcinoma that in squamous cell carcinoma. We did not find that RUNX3 hypermethylation was correlated with clinical stage or differentiated status. However, NSCLC patients with RUNX3 hypermethylation had a lower survival rate than those without RUNX3 hypermethylation. The results of this meta-analysis suggest that RUNX3 hypermethylation is associated with an increased risk and worse survival in NSCLC. RUNX3 hypermethylation, which induces inactivation of the RUNX3 gene, plays an important role in lung carcinogenesis and clinical outcome.

Mendeley readers

The data shown below were compiled from readership statistics for 20 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 20 100%

Demographic breakdown

Readers by professional status Count As %
Student > Ph. D. Student 3 15%
Researcher 3 15%
Student > Master 3 15%
Other 2 10%
Librarian 1 5%
Other 3 15%
Unknown 5 25%
Readers by discipline Count As %
Medicine and Dentistry 7 35%
Economics, Econometrics and Finance 2 10%
Environmental Science 1 5%
Agricultural and Biological Sciences 1 5%
Neuroscience 1 5%
Other 2 10%
Unknown 6 30%

Attention Score in Context

This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 10 June 2015.
All research outputs
#4,341,352
of 5,214,547 outputs
Outputs from Drug Design, Development and Therapy
#533
of 776 outputs
Outputs of similar age
#144,513
of 177,421 outputs
Outputs of similar age from Drug Design, Development and Therapy
#86
of 121 outputs
Altmetric has tracked 5,214,547 research outputs across all sources so far. This one is in the 1st percentile – i.e., 1% of other outputs scored the same or lower than it.
So far Altmetric has tracked 776 research outputs from this source. They receive a mean Attention Score of 2.2. This one is in the 1st percentile – i.e., 1% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 177,421 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 121 others from the same source and published within six weeks on either side of this one. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.